This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the obesity-and-diabetes medicine leader, faced a fresh competitive data point Monday after Novo Nordisk (NYSE:NVO) said CagriSema beat tirzepatide's 5-milligram dose in a late-stage diabetes study. Lilly shares still climbed about 1.2% to $1,166.74, suggesting investors were not treating the result as a decisive threat to the company's obesity franchise. Warning! GuruFocus has detected 3 Warning Sign with MSFT. Is LLY fairly valued? Test your thesis with our free DCF calculator.LLY GF Value chart Patients taking CagriSema lost an estimated 12.4% of their body weight versus 9.1% for patients receiving the Lilly comparator, while Novo also reported non-inferior blood-sugar reduction.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.